Abstract
P-glycoprotein (P-gp), a cell membrane protein, has been found in multidrug-resistant cancer cells. A total of 104 smears from patients with breast-cancer-associated pleural effusions and ovarian-cancer-related peritoneal effusions were studied for P-gp with the antibody C-219 and the avidin-biotin-immunoperoxidase method. Samples were taken before and 3 and 7 days after intracavitary bleomycin therapy and reaccumulation of effusion was assessed at 30 days. Smears that were P-gp-negative by the 7th day were associated with a good 30-day response to bleomycin in the majority of cases, while P-gp-positive smears were associated with a significant reaccumulation of fluid at 30 days. P-gp status is a valuable prognostic indicator of response to intracavitary bleomycin treatment in effusions from breast or ovarian cancer.
Key words: P-Glycoprotein, Immunocytochemistry, Bleomycin, Drug resistance, Malignant effusions
Abbreviation
- P-gp
P-glycoprotein
References
- Athanassiadou P, Athanassiades P, Giannioti H, Kyrkou K (1991) Immunocytochemical expression of P-glycoprotein in pleural and peritoneal tumor cells and anti neoplastic drug resistance Eur J Cancer 27 [Suppl 2]: 13071835603 [Google Scholar]
- Bezwoda W, Seymour L, Dansey R (1989) Intraperitoneal recombinant interferon-α 2b for recurrent malignant ascites due to ovarian cancer. Cancer 64:1029–1033 [DOI] [PubMed] [Google Scholar]
- Bitran J (1985) Intraperitoneal bleomycin: pharmacokinetics and results of a phase II trial. Cancer 56:2420–2423 [DOI] [PubMed] [Google Scholar]
- Bitran J, Brown C, Desser R, Kozloff M, Shapiro C, Billings A (1981) Intracavitary bleomycin for the control of malignant effusions. J Surg Oncol 16:273–277 [DOI] [PubMed] [Google Scholar]
- Chatterjee M, Robson C, Harris A (1990) Reversal of multidrug resistance by verapamil and modulation by al acid glycoprotein in wild-type and multidrug-resistant Chinese hamster ovary cell lines. Cancer Res 50:2818–2822 [PubMed] [Google Scholar]
- D'lncolci M, Broxterman H, Kalken C van (1991) Membrane transport in multidrug resistance, development and disease. Ann Oncol 2:635–639 [DOI] [PubMed] [Google Scholar]
- Duensing S, Dallmann I, Grosse J, Buer J, Lopez-Hanninen E, Deckert M, Storkel S, Kirchner H, Poliwoda H, Atzpodien J (1994) Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients. Oncology 51:309–313 [DOI] [PubMed] [Google Scholar]
- Fuqua S, Moretti-Rojas I, Schneider S, McGuire W (1987) P-glycoprotein expression in human breast cancer cells. Cancer Res 47:2103–2106 [PubMed] [Google Scholar]
- Hamed H, Fentiman IS, Chaudary MA, Rubens RD (1989) Comparison of intracavitary Bleomycin talc for control of pleural effusions secondary to carcinoma of the breast. Br J Surg 76:1266–1267 [DOI] [PubMed] [Google Scholar]
- Hsu S, Raine L, Fanges H (1991) Use of avidin biotin peroxidase complex (ABC) immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577–580 [DOI] [PubMed] [Google Scholar]
- Juliano R, Ling V (1976) A surface-glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152–162 [DOI] [PubMed] [Google Scholar]
- Kartner N, Ling V (1989) Multidrug resistance in cancer. Sci Am 26–33 [DOI] [PubMed]
- Ostrowski MJ (1986) An assessment of the long term results of controlling the reaccumulation of malignant effusions using intracavitary bleomycin. Cancer 57:721–727 [DOI] [PubMed] [Google Scholar]
- Ostrowski M, Halsall G (1982) Intracavitary bleomycin in the management of malignant effusions: a multicentre study. Cancer Treat Rep 66:1903–1907 [PubMed] [Google Scholar]
- Paladine W, Cunningham T, Sponzo R, Donavan M, Olson K, Horton J (1976) Intracavitary bleomycin in the management of malignant effusions. Cancer 38:1903–1908 [DOI] [PubMed] [Google Scholar]
- Pastan I, Gottesman M (1987) Multiple-drug resistance in human cancer. N Engl J Med 316:1388–1393 [DOI] [PubMed] [Google Scholar]
- Pretorius G, Hacher F, Bervk S, et al. (1981) The pharmacokinetics of intraperitoneal cis-platinum in refractory ovarian cancer. Obstet Gynecol 58:192–1986454868 [Google Scholar]
- Ro J, Sahin A, Ro J, Fritsche H, Hortobagyl G, Blick M (1990) Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 21:787–791 [DOI] [PubMed] [Google Scholar]
- Roberts P, Penny J, Campbell F (1995) Chemosensitisation of human adenocarcinoma cells by antisense against the multidrug resistance (MDR 1) gene. Eur J Cancer 31A [Suppl 5]: S267695974 [Google Scholar]
- Rutledge M, Robey-Cafferty S, Silva E, Bruner J (1990) Monoclonal antibody C219 detection of the multidrug-resistant protein P-glycoprotein in routinely processed tissues: a study of 36 cases of ovarian carcinoma. Mod Pathol 3:298–301 [PubMed] [Google Scholar]
- Sicik B (1993) Bleomycin. In: Cuitkovic E, Droz J, Armand J, Khoury S (eds) Handbook of chemotherapy in clinical oncology. Scientific Communication International, Paris, pp 296–302 [Google Scholar]
- Takeshita H, Gebhardt C, Springfield S, et al. (1996) Experimental models for the study of drug resistance in osteosarcoma: P-glycoprotein-positive, murine osteosarcoma cell lines. J Bone Joint Surg Am 3:366–375 [DOI] [PubMed] [Google Scholar]
- Verrelle P, Meissonnier F, Fonck Y, et al. (1991) Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 83:111–116 [DOI] [PubMed] [Google Scholar]
- Weinstein R, Kuszak J, Kluskens L, Coon J (1990) P-glycoproteins in pathology: the multidrug resistance gene family in humans. Hum Pathol 21:34–48 [DOI] [PubMed] [Google Scholar]
- West R, Boyle E, Grignon D, Chin-Yee I (1994) P-glycoprotein expression in non-Hodgkin's lymphoma. Int J Oncol 4:1237–1242 [DOI] [PubMed] [Google Scholar]